## Treatment of OFF Episodes in Parkinson's Disease: An Evaluation of Physician Insights

Eric J. Pappert, MD;<sup>1</sup> Albert Agro, PhD<sup>1</sup>; Nigel deGruyther, B.Sc.Pharm, MBA<sup>1</sup>

<sup>1</sup>Cynapsus Therapeutics, Toronto, Ontario, Canada

### CYNAPSUS

#### **BACKGROUND**

OFF episodes in PD have a significant negative impact on QoL of patients

## **OBJECTIVE**

Determine physician practices in the treatment of OFF episodes in patients with Parkinson's disease.

## **METHODS**

A survey was sent to 405 physicians who treat patients with PD

- 175 primary care physicians [PCP],
- 97 neurologists [NEURO] and
- 36 movement disorder specialists [MOV]).


The survey queried physician practices and attitudes regarding the treatment of OFF episodes


### **SURVEY RESULTS**


- 102 surveys returned:
  - 50 Primary Care Physicians (PCP),
  - 30 Neurologists (NEURO) and
  - 22 Movement Disorder Specialists (MOV)


**Table 1: Respondent Demographics** 

Respondent Demographics	All N=102	PCP N=50	NEURO and MOV N=52
# of Yrs Treating PD since Residence, mean	16.7	16.3	17.1
# of PD patients/month, mean	75.4	46.2	103.3
# of Levodopa Rx/month, mean	63.6	40.1	86.3














## **RESULTS** (continued)











# **CONCLUSIONS**

- Physicians are concerned about OFF episodes. Physicians feel that their patients are
- aware of OFF episodes. Physicians feel that there is a fairly high
- level of unmet need regarding treatment options for OFF episodes.

**ACKNOWLEDGEMENTS/DISCLOSURES** 

This study was supported by Cynapsus Therapeutics. EJP, ND, and

AA are employees of Cynapsus Therapeutics and hold stock or stock

options.